- Home
- ALLO vs MDXG Comparison
ALLO vs MDXG Comparison
Compare ALLO & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | MDXG |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | 152 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.1M | 625.6M |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ALLO | MDXG |
|---|---|---|
| Price | $2.09 | $4.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | $8.35 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 5.9M | 1.5M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $1.04 | $3.03 |
| 52 Week High | $4.46 | $7.97 |
Technical Indicators
Market Signals| Indicator | ALLO | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 54.33 |
| Support Level | $2.07 | $4.11 |
| Resistance Level | $2.25 | $4.47 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 65.85 | 61.11 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.